World Cancer Report Webinar Series - HPV vaccination

Thursday 19 November 2020

"Learnings from Australia’s HPV vaccination experience" and "Trends in HPV vaccination from a global perspective"


Thirteen sexually transmitted human papillomavirus (HPV) subtypes are responsible for all cases of cervical cancer globally (570 000 cases) and a proportion of cases of other anogenital and oropharyngeal cancers (totalling 120 000 cases). 

The safety and high efficacy of HPV vaccines have been established in clinical trials. Data are accruing on the effectiveness of HPV vaccination programmes, including strong herd immunity effects, and reduction in cervical cancer rates. HPV vaccination programmes are the cornerstone of the World Health Organization (WHO) Global Strategy on Cervical Cancer Elimination. 

This webinar will describe the impact of HPV vaccination in Australia, which implemented one of the earliest and most successful vaccination programmes. This will be followed by an up-to-date overview of global progress in the implementation of HPV vaccination, with a focus on challenges in low- and middle-income countries


  • Dr Julia Brotherton, public health physician and epidemiologist
    Medical Director, Population Health, VCS Foundation, Melbourne, Australia
  • Mr Paul Bloem, public health practitioner
    HPV Vaccine Strategy Lead, World Health Organization, Geneva, Switzerland


  • Chaired by Dr Gary Clifford. Head of the Infections and Cancer Epidemiology Group
    International Agency for Research on Cancer (IARC), World Health Organization
    Lyon, France


  • The session will last 1 hour.
  • "Key learnings from Australia’s HPV vaccination experience”: Dr Julia Brotherton
  • "Key trends in HPV vaccination from a global perspective": Mr Paul Bloem
  • Questions and Answers

Thursday 19 November 2020
10:00 CET

Click to check local time

Event Information

International Agency for Research on Cancer (IARC)
This event is under the auspices of UICC
Last update: 
Monday 16 November 2020